Many ROR1 mAbs have been designed and demonstrate significant preclinical efficacy [35,36,37]; cirmtuzumab (UC-951) [38] is currently in phase I–II of clinical trials for CLL and breast cancer. The gene discussed is ROR1; the disease is breast carcinoma.